![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FAM214B |
Gene summary for FAM214B |
![]() |
Gene information | Species | Human | Gene symbol | FAM214B | Gene ID | 80256 |
Gene name | family with sequence similarity 214 member B | |
Gene Alias | KIAA1539 | |
Cytomap | 9p13.3 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q7L5A3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80256 | FAM214B | C21 | Human | Oral cavity | OSCC | 4.61e-10 | 3.31e-01 | 0.2678 |
80256 | FAM214B | C30 | Human | Oral cavity | OSCC | 3.58e-18 | 1.08e+00 | 0.3055 |
80256 | FAM214B | C38 | Human | Oral cavity | OSCC | 3.43e-02 | 4.30e-01 | 0.172 |
80256 | FAM214B | C51 | Human | Oral cavity | OSCC | 9.69e-04 | 3.81e-01 | 0.2674 |
80256 | FAM214B | C06 | Human | Oral cavity | OSCC | 1.08e-09 | 1.18e+00 | 0.2699 |
80256 | FAM214B | SYSMH1 | Human | Oral cavity | OSCC | 2.28e-09 | 1.97e-01 | 0.1127 |
80256 | FAM214B | SYSMH3 | Human | Oral cavity | OSCC | 2.20e-10 | 3.11e-01 | 0.2442 |
80256 | FAM214B | SYSMH6 | Human | Oral cavity | OSCC | 4.25e-04 | 1.19e-01 | 0.1275 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Oral Cavity | ![]() | EOLP: Erosive Oral lichen planus |
LP: leukoplakia | ||
NEOLP: Non-erosive oral lichen planus | ||
OSCC: Oral squamous cell carcinoma |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FAM214B | SNV | Missense_Mutation | novel | c.958C>T | p.Pro320Ser | p.P320S | Q7L5A3 | protein_coding | tolerated(0.92) | benign(0) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | c.395N>C | p.Val132Ala | p.V132A | Q7L5A3 | protein_coding | tolerated(1) | benign(0) | TCGA-BG-A0M4-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | SD | |
FAM214B | SNV | Missense_Mutation | rs780611055 | c.320C>T | p.Pro107Leu | p.P107L | Q7L5A3 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-BG-A3EW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | c.1049N>A | p.Gly350Asp | p.G350D | Q7L5A3 | protein_coding | deleterious(0) | probably_damaging(0.99) | TCGA-BS-A0TA-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | PD | |
FAM214B | SNV | Missense_Mutation | rs778936766 | c.1561N>A | p.Glu521Lys | p.E521K | Q7L5A3 | protein_coding | deleterious(0.05) | probably_damaging(0.936) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | rs150303642 | c.1436G>A | p.Arg479His | p.R479H | Q7L5A3 | protein_coding | deleterious(0.01) | possibly_damaging(0.643) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | c.477C>A | p.Asp159Glu | p.D159E | Q7L5A3 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.978) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FAM214B | SNV | Missense_Mutation | novel | c.301N>A | p.Leu101Ile | p.L101I | Q7L5A3 | protein_coding | deleterious(0.01) | benign(0.042) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
FAM214B | SNV | Missense_Mutation | rs573042192 | c.965G>A | p.Arg322Gln | p.R322Q | Q7L5A3 | protein_coding | deleterious(0.02) | possibly_damaging(0.805) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
FAM214B | SNV | Missense_Mutation | rs538819243 | c.1073N>A | p.Arg358Gln | p.R358Q | Q7L5A3 | protein_coding | tolerated(0.12) | benign(0.005) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |